semaglutide label Doctors Petition FDA for Labeling Changes on Wegovy including heart disease FDA warns about fake Ozempic

I first came across red light therapy while I was researching sleep disorders

The benefits in ASCVD risk reduction with GLP-1RA are evidenced by 14% risk reduction in cardiovascular mortality with an NNTB of 207 to prevent one event, 13% MACE reduction with an NNT of 67 to prevent one event and 12% risk reduction in stroke with an NNT of 335 to prevent one event, along with their favourable safety profile of 6% increased overall adverse events

All treatments require consultation with a licensed healthcare provider

As public interest in investigational medical products continues to increase, developers may be under greater pressure to make such products available to patients and their health care providers